Skip to main content
Fig. 3 | Clinical Epigenetics

Fig. 3

From: Histone methyltransferases EHMT1 and EHMT2 (GLP/G9A) maintain PARP inhibitor resistance in high-grade serous ovarian carcinoma

Fig. 3

EHMT2 is upregulated in advanced and chemoresistant HGSOC, and elevated EHMT1/2 correlates with poorer clinical outcomes. a EHMT2 mRNA expression in Borderline versus HGSOC tumors. b EHMT2 mRNA expression in grade 1, 2, and 3 ovarian tumors. c Relative EHMT2 copy number correlated to ovarian cancer stage III or IV tumors. d Relative intensity of EHMT2 in carboplatin sensitive (n = 3) and resistant (n = 3) HGSOC tumors. Tumors analyzed in triplicate are color-coded. e, f Analysis of TCGA microarray data. A combined median expression was calculated for EHMT1 and EHMT2 to distinguish patients with low or high EHMT1/2 expression. Kaplan-Meier curves were generated against (e) progression-free survival (N = 614) and (f) overall survival (N = 655)

Back to article page